$22.22
Arrowhead Pharmaceuticals is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 525 staff and has a trailing 12-month revenue of around $19.6 million.
Our top picks for where to buy Arrowhead Pharmaceuticals stock
How to buy Arrowhead Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ARWR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Arrowhead Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)
Use our graph to track the performance of ARWR stocks over time.Arrowhead Pharmaceuticals shares at a glance
Latest market close | $22.22 |
---|---|
52-week range | $20.67 - $39.83 |
50-day moving average | $26.00 |
200-day moving average | $27.59 |
Wall St. target price | $47.21 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-4.65 |
Is it a good time to buy Arrowhead Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arrowhead Pharmaceuticals price performance over time
Historical closes compared with the close of $22.22 from 2024-09-06
1 week (2024-08-30) | -6.76% |
---|---|
1 month (2024-08-07) | -11.12% |
3 months (2024-06-07) | -7.07% |
6 months (2024-03-07) | -33.07% |
1 year (2023-09-07) | -26.47% |
---|---|
2 years (2022-09-07) | -43.27% |
3 years (2021-09-07) | 65.62 |
5 years (2019-09-06) | 31.51 |
Arrowhead Pharmaceuticals financials
Revenue TTM | $19.6 million |
---|---|
Gross profit TTM | $240.7 million |
Return on assets TTM | -40.72% |
Return on equity TTM | -151.84% |
Profit margin | 0% |
Book value | $2.66 |
Market Capitalization | $3 billion |
TTM: trailing 12 months
Arrowhead Pharmaceuticals share dividends
We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.
Have Arrowhead Pharmaceuticals's shares ever split?
Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.
Arrowhead Pharmaceuticals share price volatility
Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $20.67 up to $39.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 0.966. This would suggest that Arrowhead Pharmaceuticals's shares are less volatile than average (for this exchange).
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.
Frequently asked questions
nullWhat percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 4.466% of Arrowhead Pharmaceuticals shares are held by insiders and 80.54% by institutions. How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 525 work at Arrowhead Pharmaceuticals. When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September. Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007 What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question